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background:  Optimal platelet inhibition is paramount in patients undergoing percutaneous coronary intervention. High platelet reactivity 
(PR) is associated with thrombotic complications; low reactivity is associated with bleeding risk, particularly in older patients. Although 
wide inter-individual variation exists in response to antiplatelet agents such as adenosine diphosphate (ADP) receptor antagonists, few 
data exist regarding pre-procedure PR in older patients with non-ST-elevation acute coronary syndrome (NSTEACS), undergoing invasive 
treatment.
methods:  Platelet reactivity was evaluated in 49 ≥75 year old patients, who presented with NSTEACS, for invasive management, 
to a tertiary cardiac centre. Reactivity to ADP and thrombin receptor agonist peptide-6 (TRAP) was evaluated by multiple electrode 
aggregometry, using the point-of-care Multiplate™ Analyzer (Roche, Switzerland). High PR was defined as: ADP ≥ 46U or TRAP ≥ 113U 
(literature-derived; associated with thrombosis), low PR was defined as ADP ≤ 19U or TRAP ≤ 50 (associated with bleeding). All data are 
presented: mean (standard deviation).
Results:  49 patients (mean age 82.0 [4.6], 55.1% male) had a pre-procedural ADP of 22.8U (13.1) and TRAP of 87.3U (28.4). Significant 
inter-individual variation was observed (ADP ranged from 2.5 - 49.3U, TRAP ranged from 23.6 - 136.3U). 11 (22.4%) patients were 
classified as having high PR, and 24 (49%) had low PR, measured by either ADP or TRAP. Platelet reactivity status did not correlate with 
baseline variables, including age (p = 0.64), sex (p = 0.68), smoking status (p = 0.24), diabetes (p = 0.78), history of ischaemic heart 
disease (p = 0.38) or frailty (p = 0.07). A significant association between TRAP and platelet count was observed (p = 0.02).
conclusion:  Further optimisation of antiplatelet pharmacotherapy is required in older patients presenting with NSTEACS. Nearly half had 
low platelet reactivity, which could increase risk of bleeding. Recommendations, in particular those relating to drug dosage from randomized 
studies, consisting of primarily younger patients, may not be applicable to older cohorts. Further studies in this cohort are warranted.
